发布求助
文献互助 智能选刊 最新文献

Journal of Chemotherapy最新文献

筛选
英文 中文
Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. COVID-19患者的临床疗效比较：系统综述和荟萃分析。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-09 DOI: 10.1080/1120009X.2024.2352268
Mingyang Yang, Junzhao Liu, Linna Luo, Kaili Dai
{"title":"Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis.","authors":"Mingyang Yang, Junzhao Liu, Linna Luo, Kaili Dai","doi":"10.1080/1120009X.2024.2352268","DOIUrl":"10.1080/1120009X.2024.2352268","url":null,"abstract":"","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"94-96"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical value of circulating tumour cells in evaluating the efficacy of continuous hepatic arterial infusion among colorectal cancer patients. 循环肿瘤细胞在评估结直肠癌患者持续肝动脉输注疗效中的临床价值。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-06 DOI: 10.1080/1120009X.2024.2333650
Erying Zhang, Haifei Li, Caiyun Liu, Haikun Zhou, Bo Liu, Chengbao Feng
{"title":"Clinical value of circulating tumour cells in evaluating the efficacy of continuous hepatic arterial infusion among colorectal cancer patients.","authors":"Erying Zhang, Haifei Li, Caiyun Liu, Haikun Zhou, Bo Liu, Chengbao Feng","doi":"10.1080/1120009X.2024.2333650","DOIUrl":"10.1080/1120009X.2024.2333650","url":null,"abstract":"<p><p>Few studies have been conducted to evaluate the efficacy of HAIC using circulating tumour cells (CTCs). In this study, a total of 100 patients who received HAIC treatment and CTC detection were selected. The results showed that after HAIC treatment, the levels of CTC, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) decreased. Postoperative progression-free survival (PFS) rates between patients with positive and negative preoperative CTC results, and for CA19-9, CEA were significantly different. The positive rate of CTCs was 61% before chemotherapy and 23% after chemotherapy, and the correlation coefficient between the two was 0.385. Those whose CTC values increased after chemotherapy had shorter PFS rates. CTCs are an independent predictor of recurrence. Patients with CTC-positive results are more susceptible to recurrence. The CTC count in peripheral blood has a close bearing on the postoperative chemotherapy efficacy of patients with CRC and affects patients' PFS.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"76-84"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem.
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-01-23 DOI: 10.1080/1120009X.2025.2456327
Nami Obara, Toshiaki Komatsu, Kazuyoshi Shiratsu, Yuto Akamada, Katsuya Otori
{"title":"Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem.","authors":"Nami Obara, Toshiaki Komatsu, Kazuyoshi Shiratsu, Yuto Akamada, Katsuya Otori","doi":"10.1080/1120009X.2025.2456327","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2456327","url":null,"abstract":"<p><p>This retrospective study investigated whether piperacillin/tazobactam (PIPC/TAZ) monotherapy affects renal function compared to cefepime (CFPM) or meropenem (MEPM) monotherapy. Hospitalized patients who received PIPC/TAZ, CFPM, or MEPM monotherapy between April 2021 and December 2022 were enrolled in this study. We used inverse probability of treatment weighting (IPTW) to balance baseline characteristics and compare the incidence of acute kidney injury (AKI). Overall, 259, 104, and 98 patients were enrolled in the PIPC/TAZ, CFPM, and MEPM groups, respectively. After applying IPTW, PIPC/TAZ administration was found to be significantly associated with an increased risk of AKI (odds ratio [OR]: 6.75, 95% confidence interval [CI]: 1.30-34.8, <i>p</i> = 0.023 compared to CFPM; and OR: 7.71, 95% CI: 1.00-59.2, <i>p</i> = 0.049 compared to MEPM). PIPC/TAZ monotherapy may be associated with a higher risk of AKI than CFPM or MEPM monotherapy.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic drug monitoring-guided high-dose isavuconazole therapy for invasive pulmonary aspergillosis in a patient on extracorporeal membrane oxygenation support. 治疗药物监测引导下大剂量异唑康唑治疗侵袭性肺曲霉病1例体外膜氧合支持。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-01-19 DOI: 10.1080/1120009X.2025.2452694
Alba Pau-Parra, Manuel Sosa Garay, Laura Doménech Moral, Mónica Díez Poch, María Martínez Pla, Elisabet Gallart, Jaume Vima Bofarull, Xavier Nuvials, Sonia García-García, Josep María Doménech Vila, Laura Planas Viñuales, Iván Cruz López, Pilar Lalueza Broto, Maria Queralt Gorgas Torner, Ricard Ferrer, Jordi Riera
{"title":"Therapeutic drug monitoring-guided high-dose isavuconazole therapy for invasive pulmonary aspergillosis in a patient on extracorporeal membrane oxygenation support.","authors":"Alba Pau-Parra, Manuel Sosa Garay, Laura Doménech Moral, Mónica Díez Poch, María Martínez Pla, Elisabet Gallart, Jaume Vima Bofarull, Xavier Nuvials, Sonia García-García, Josep María Doménech Vila, Laura Planas Viñuales, Iván Cruz López, Pilar Lalueza Broto, Maria Queralt Gorgas Torner, Ricard Ferrer, Jordi Riera","doi":"10.1080/1120009X.2025.2452694","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2452694","url":null,"abstract":"<p><p>We review the case of a 58-year-old female on extracorporeal membrane oxygenation (ECMO) support diagnosed with invasive pulmonary aspergillosis (IPA). Intravenous isavuconazole was started, requiring dose escalation to achieve isavuconazole trough concentration (ISA-Cmin) within the therapeutic range (2.5-5.0 μg/mL). For more than 4 months, she maintained a dose of 200 mg q12h, with a median ISA-Cmin of 3.4 (interquartile range [IQR]: 3.1-4.9) µg/mL. Throughout this interval, 17 assessments of ISA-Cmin were performed (weekly). Of these, 82% (14/17) were within the therapeutic range, with an intra-individual variability of 36.8%. Although no signs of hepatotoxicity were observed, she experienced short-term gastrointestinal adverse events related to potential isavuconazole over-exposure (ISA-Cmin > 5.0 μg/mL). ECMO circuit changes did not appear to affect ISA-Cmin. She was not obese (IMC ≈ 25 kg/m<sup>2</sup>) and did not require other extracorporeal therapy, but hypoalbuminemia may have contributed to an increase in unbound isavuconazole fraction and consequently its clearance.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers. 晚期或转移性胃食管癌中与生存无关的免疫相关不良事件
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-01-07 DOI: 10.1080/1120009X.2024.2448644
Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur
{"title":"Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers.","authors":"Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur","doi":"10.1080/1120009X.2024.2448644","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2448644","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studies have shown improved treatment responses in patients with IRAEs compared to those without IRAEs in various cancer types such as melanoma and non-small cell lung cancer. We performed a single-institution retrospective study to characterize IRAE incidence and association with treatment response in advanced GEC. We identified 70 patients with GEC who received ICI therapy; 20 (29%) developed an IRAE of any magnitude. The most common were colitis (35%) hypothyroidism (25%) and pneumonitis (20%). Median PFS and OS were not statistically different between IRAE and nonIRAE groups (10.4 vs. 11.3 months <i>p</i> = 0.6 and 11.0 vs. 12.9 months <i>p</i> = 1.0, respectively). This is in contrast to studies in other cancer types that have suggested association between IRAE and improved outcomes.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature. 在21外显子EGFR（L858R）突变的非小细胞肺癌中，获得性CCDC6::RET基因融合作为奥西替尼耐药机制，以及奥西替尼和塞尔珀卡替尼的成功治疗：一例报告和文献综述。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-01-05 DOI: 10.1080/1120009X.2024.2445909
Maud Lormans, Peter Van Haecke, Ingel Demedts
{"title":"An acquired CCDC6::<i>RET</i> gene fusion as resistance mechanism for Osimertinib in exon 21 <i>EGFR(L858R)</i>-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.","authors":"Maud Lormans, Peter Van Haecke, Ingel Demedts","doi":"10.1080/1120009X.2024.2445909","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445909","url":null,"abstract":"<p><p><b>Background:</b> Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the recommended front-line therapy for treatment-naïve patients with advanced stage EGFR mutated Non-Small Cell Lung Cancer (NSCLC), with better tolerance and outcomes compared to chemotherapy. However, patients inevitably develop resistance to EGFR-TKI. The extent of progression free survival depends on intrinsic or acquired on-target/off-target mechanisms of EGFR-TKI resistance. Overcoming these acquired rearrangements remains challenging in modern precision medicine. In case of disease progression during treatment with an EGFR-TKI, rebiopsy is recommended to search for a potential resistance mechanism. However, the therapeutic potential of these resistance mechanisms represents an unmet need in thoracic oncology. <b>Case</b><b>Presentation:</b> We present a case of a 78-year-old woman with stage IVB EGFR-mutated NSCLC in whom an acquired RET Gene Fusion was identified as the <i>EGFR</i>-independent resistance mechanism. Additionally, a combined therapy of Osimertinib and Selpercatinib showed a durable oncological response with 14 months of progression free survival in the absence of adverse events. <b>Conclusion:</b> Addition of Selpercatinib to Osimertinib in an EGFR-mutated NSCLC patient with an acquired RET fusion was well tolerated and created a clinical benefit. Further prospective investigation into these novel combination strategies is needed as resistance mechanisms could serve as possible targets for new therapy approaches.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains. 德拉沙星与其他抗多重耐药铜绿假单胞菌菌株的体外相互作用评价。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-26 DOI: 10.1080/1120009X.2024.2445910
Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er
{"title":"Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant <i>Pseudomonas aeruginosa</i> strains.","authors":"Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er","doi":"10.1080/1120009X.2024.2445910","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445910","url":null,"abstract":"<p><p>Novel therapeutic interventions are required to address the critical antimicrobial resistance caused by multidrug-resistant <i>Pseudomonas aeruginosa</i> (MDR-PA) infections. This study examines the impact of combining delafloxacin with antibiotics on MDR-PA isolated from various samples. The minimum inhibitory concentrations (MICs) of delafloxacin, alone and in combination with other antibiotics, were determined against forty distinct MDR-PA isolates using the broth microdilution method. Time-kill curve assays were used to determine the bactericidal and synergistic effects of delafloxacin alone and in combination with other antibiotics <i>in vitro</i> against the selected five strains. Our studies showed delafloxacin exhibited four times greater in-vitro activity against MDR-PA strains than levofloxacin compared with both MIC<sub>50</sub> and MIC<sub>90</sub> results. Delafloxacin + tobramycin and delafloxacin + ceftazidime/avibactam showed synergy in two out of five strains tested at concentrations equal to the MIC. The outcomes of this research also suggest that these combinations may replace therapy for MDR-PA strains.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiological markers for immunotherapeutics: a review. 免疫治疗生理学标志物研究进展。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-22 DOI: 10.1080/1120009X.2024.2443701
Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, Trinkal Khutere, Surendra H Bodakhe
{"title":"Physiological markers for immunotherapeutics: a review.","authors":"Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, Trinkal Khutere, Surendra H Bodakhe","doi":"10.1080/1120009X.2024.2443701","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2443701","url":null,"abstract":"<p><p>Immunotherapy has been advanced through multiple approaches, including immunogenic cytokines, monoclonal antibodies, therapeutic vaccinations, adoptive cell transfer, stem cell transplantation, and oncolytic viruses. This review analyses various strategies in genomics, transcriptomics, single-cell techniques, computational analysis, big data, and imaging technologies for the identification of tumour microbiota and microenvironments. Immunotherapy is becoming acknowledged as a feasible cancer treatment method, facilitating innovative cancer medicines and personalized medicine techniques.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-24"},"PeriodicalIF":1.9,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation. 不同肾功能重症患者利奈唑胺抗革兰阳性球菌给药方案的优化：蒙特卡罗模拟。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-13 DOI: 10.1080/1120009X.2024.2440192
Hongyu Qiu, Hao Li, Lingti Kong
{"title":"Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation.","authors":"Hongyu Qiu, Hao Li, Lingti Kong","doi":"10.1080/1120009X.2024.2440192","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2440192","url":null,"abstract":"<p><p>To promote the accurate administration of linezolid, this study aimed to evaluate its dosage regimens in critically ill patients with varying renal functions. This evaluation was based on a combined analysis of pharmacokinetic (PK), pharmacodynamic (PD), and toxicodynamic (TD) indices. The percentage of therapeutic target attainment (PTTA) was used as the index for PK/PD/TD, defined as simultaneously meeting two PK/PD criteria (AUC<sub>0-24h</sub>/MIC ≥ 100 and C<sub>ss</sub> between 2.6-7.8 mg/L) and adjusted for toxicity probability, with MICs ranging from 0.5 to 8 mg/L. The recommended doses of linezolid for patients: 600 mg every 12 h for normal renal function or mild renal impairment, 300 mg every 12 h for severe renal impairment, 450 mg every 12 h for moderate renal impairment, and 600 mg every 8 h for supra-normal renal function. In conclusion, specific dosing regimens should be adopted for patients with varying renal functions, combined with therapeutic drug monitoring, to ensure the safety and efficacy of linezolid.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapy-related hand-foot syndrome: a review. 治疗相关手足综合征：综述。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2024-12-09 DOI: 10.1080/1120009X.2024.2437336
Bilha Baby, Nevin Sam, Narmadha M P, Gopikrishnan Anjaneyan, Rakesh M P
{"title":"Therapy-related hand-foot syndrome: a review.","authors":"Bilha Baby, Nevin Sam, Narmadha M P, Gopikrishnan Anjaneyan, Rakesh M P","doi":"10.1080/1120009X.2024.2437336","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2437336","url":null,"abstract":"<p><p>Anti-tumor drugs cause hand-foot syndrome through a variety of pathogenic mechanisms. Some chemotherapeutic medications that can cause HFS include 5FU, doxorubicin, capecitabine, high dose cytarabine, and others. These medications each have a unique mechanism resulting in HFS. The histopathological characteristics, clinical manifestations, and variations in gender, ethnicity, or genetic makeup might also impact the development of HFS as an adverse drug reaction. Even though the disease might not become life-threatening, it is nevertheless vital to manage it with therapeutic interventions or by withholding the medication in order to enhance the patient's outcome. Current developments in pharmacological and non-pharmacological therapeutic approaches for managing symptoms also emphasis the same.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信